Replies to post #252283 on Biotech Values

[DewDiligence]

ZEAL—Petrelintide should not be confused with Survodutide, the GLP-1/GC agonist ZEAL is co-developing with Boehringer Ingelheim (#msg-172204950).

[DewDiligence]

ZEAL.CO sells 8.35M shares @DKK843/sh—(~$121)—a 4% premium to_yesterday’s_closing_price:

https://www.globenewswire.com/news-release/2024/06/25/2904185/0/en/Zealand-Pharma-announces-completion-of-an-upsized-equity-offering-of-8-35-million-new-ordinary-shares-raising-gross-proceeds-of-USD-1-billion-DKK-7-billion.html

Gross proceeds from the offering are $1.0B, implying net proceeds of approximately $940M. Wow.